Pfizer Biosimilars:

Available Speaker Programs

Biosimilars: An Overview for Health Care Professionals

This expert-led, peer-to-peer program will provide health care professionals (HCPs) with an understanding of why biosimilars are being developed and the scientific and clinical considerations used by the US Food and Drug Administration (FDA) to grant them approval.

Attendees will gain an increased knowledge of the types of scientific and clinical data that are required for biosimilar approval by the FDA. This foundation may assist HCPs who choose to incorporate biosimilars into their practice or institution.

Key Topics:

- Background and current state of biologics and biosimilars
- The evolving landscape of biosimilar development in the United States and Europe
- Manufacturing and development of biosimilars
- The requirements and processes by which the FDA evaluates biosimilars for approval
- Extrapolation and interchangeability
- Potential impact of biosimilars on the health care system

Duration: 1 hour

A Practical Approach to Biosimilar Implementation

This expert-led, peer-to-peer program is designed to provide an overview of essential considerations when evaluating biosimilars for formulary inclusion. It also highlights important considerations for the implementation of biosimilars at the HCP's institution or practice.

Attendees will gain increased understanding of key topics of consideration for biosimilars when deciding to include them on the institution or practice formulary. It is recommended that attendees participate in the Biosimilars Overview Program OR have an understanding of biosimilar and extrapolation regulatory and development concepts as a foundation to build upon.

Key Topics:

- Laying the foundation for evaluating a biosimilar
- Biosimilar efficacy and safety: considerations for P&T committees
- Manufacturer, pharmacovigilance, and reimbursement considerations

Duration: 1 hour

For more information or to arrange a speaker program, contact your Pfizer Biosimilars Representative.

October 2016.

Pfizer Biosimilars